SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 221 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.36 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,192,580 | -12.8% | 79,528 | -4.9% | 0.00% | 0.0% |
Q2 2023 | $2,513,189 | -1.7% | 83,606 | -81.7% | 0.00% | 0.0% |
Q1 2023 | $2,556,748 | -17.2% | 456,415 | +427.0% | 0.00% | -50.0% |
Q4 2022 | $3,089,334 | +15.7% | 86,609 | +9.8% | 0.00% | 0.0% |
Q3 2022 | $2,671,000 | +27.2% | 78,904 | +8.7% | 0.00% | +100.0% |
Q2 2022 | $2,100,000 | -9.3% | 72,620 | +1.4% | 0.00% | 0.0% |
Q1 2022 | $2,316,000 | +16.3% | 71,644 | +4.9% | 0.00% | 0.0% |
Q4 2021 | $1,992,000 | +36.2% | 68,329 | +24.5% | 0.00% | 0.0% |
Q3 2021 | $1,463,000 | -2.6% | 54,873 | +12.5% | 0.00% | 0.0% |
Q2 2021 | $1,502,000 | +47.1% | 48,774 | +25.1% | 0.00% | 0.0% |
Q1 2021 | $1,021,000 | +192.6% | 38,996 | +181.5% | 0.00% | – |
Q4 2020 | $349,000 | +71.1% | 13,853 | +41.6% | 0.00% | – |
Q3 2020 | $204,000 | -18.4% | 9,782 | -7.0% | 0.00% | – |
Q2 2020 | $250,000 | +25.0% | 10,523 | -5.2% | 0.00% | – |
Q1 2020 | $200,000 | -48.3% | 11,096 | -32.0% | 0.00% | – |
Q4 2019 | $387,000 | -48.3% | 16,326 | -40.1% | 0.00% | -100.0% |
Q3 2019 | $748,000 | -40.7% | 27,234 | -28.5% | 0.00% | -50.0% |
Q2 2019 | $1,261,000 | -6.9% | 38,102 | -1.4% | 0.00% | 0.0% |
Q1 2019 | $1,354,000 | +8.1% | 38,644 | +2.4% | 0.00% | 0.0% |
Q4 2018 | $1,253,000 | +35.9% | 37,724 | +144.9% | 0.00% | 0.0% |
Q2 2018 | $922,000 | +24.1% | 15,406 | -5.0% | 0.00% | 0.0% |
Q1 2018 | $743,000 | -72.8% | 16,212 | -76.4% | 0.00% | -66.7% |
Q4 2017 | $2,734,000 | +2.6% | 68,599 | +2.9% | 0.01% | 0.0% |
Q3 2017 | $2,666,000 | -12.3% | 66,635 | -5.6% | 0.01% | -25.0% |
Q2 2017 | $3,040,000 | +273.9% | 70,577 | +171.3% | 0.01% | +166.7% |
Q1 2017 | $813,000 | +19.9% | 26,011 | -3.2% | 0.00% | +50.0% |
Q4 2016 | $678,000 | -6.2% | 26,876 | -8.0% | 0.00% | -33.3% |
Q3 2016 | $723,000 | -5.9% | 29,227 | -22.4% | 0.00% | 0.0% |
Q2 2016 | $768,000 | +27.8% | 37,681 | -4.4% | 0.00% | 0.0% |
Q1 2016 | $601,000 | +111.6% | 39,418 | +86.8% | 0.00% | +200.0% |
Q4 2015 | $284,000 | +6.4% | 21,098 | +11.0% | 0.00% | 0.0% |
Q3 2015 | $267,000 | +32.8% | 19,014 | +60.4% | 0.00% | 0.0% |
Q2 2015 | $201,000 | – | 11,856 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
S&T BANK/PA | 215,578 | $5,943 | 1.15% |
Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |